1-10 of 10
Andrea Wang-Gillam
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy

Patrick M. Grierson, Rama Suresh, Benjamin Tan, Katrina S. Pedersen, Manik Amin, Haeseong Park, Nikolaos A. Trikalinos, Jingxia Liu, Nicholas Boice, Amberly Brown, Sapana Bansod, Andrea Wang-Gillam, Kian-Huat Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4733–4739.
https://doi.org/10.1158/1078-0432.CCR-23-1405
Published: 01 December 2023
View article titled, A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
Open the PDF for A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4698.
https://doi.org/10.1158/1078-0432.CCR-23-2993
Published: 14 November 2023
View article titled, Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
Open the PDF for Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study in another window
Journal Articles

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Gregory L. Beatty, Devora Delman, Jiayi Yu, Mingen Liu, Joey H. Li, Liti Zhang, Jae W. Lee, Renee B. Chang, Nathan Bahary, Eugene P. Kennedy, Andrea Wang-Gillam, Gabriela R. Rossi, Ignacio Garrido-Laguna
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3514–3525.
https://doi.org/10.1158/1078-0432.CCR-23-0535
Published: 01 September 2023
View article titled, Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Open the PDF for Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration in another window
Includes: Supplementary data
Journal Articles

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5254–5262.
https://doi.org/10.1158/1078-0432.CCR-22-0308
Published: 15 December 2022
View article titled, Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Open the PDF for Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Filip Janku, Halle Huihong Zhang, Abdulmohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R. Shepard, Thorunn Helgason, Tyler Masters, David S. Hong, Sarina A. Piha-Paul, Daniel D. Karp, Mark Klang, Steven Y. Huang, Divya Sakamuri, Anjali Raina, Jean Torrisi, Stephen B. Solomon, Alice Weissfeld, Ernest Trevino, Gary DeCrescenzo, Amanda Collins, Maria Miller, Jennifer L. Salstrom, Ronald L. Korn, Linping Zhang, Saurabh Saha, Alexey A. Leontovich, David Tung, Brent Kreider, Mary Varterasian, Khashayarsha Khazaie, Mrinal M. Gounder
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 96–106.
https://doi.org/10.1158/1078-0432.CCR-20-2065
Published: 04 January 2021
View article titled, Intratumoral Injection of <em>Clostridium novyi</em>-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Open the PDF for Intratumoral Injection of <em>Clostridium novyi</em>-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

Annie A. Wu, Katherine M. Bever, Won Jin Ho, Elana J. Fertig, Nan Niu, Lei Zheng, Rose M. Parkinson, Jennifer N. Durham, Beth Onners, Anna K. Ferguson, Cara Wilt, Andrew H. Ko, Andrea Wang-Gillam, Daniel A. Laheru, Robert A. Anders, Elizabeth D. Thompson, Elizabeth A. Sugar, Elizabeth M. Jaffee, Dung T. Le
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5129–5139.
https://doi.org/10.1158/1078-0432.CCR-20-1025
Published: 01 October 2020
View article titled, A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Open the PDF for A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, III, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5493–5502.
https://doi.org/10.1158/1078-0432.CCR-18-2992
Published: 13 September 2019
View article titled, Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Open the PDF for Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) in another window
Includes: Supplementary data
Journal Articles

Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

Daoxiang Zhang, Lin Li, Hongmei Jiang, Brett L. Knolhoff, Albert C. Lockhart, Andrea Wang-Gillam, David G. DeNardo, Marianna B. Ruzinova, Kian-Huat Lim
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (7): 1748–1759.
https://doi.org/10.1158/1078-0432.CCR-16-1121
Published: 02 April 2017
View article titled, Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Open the PDF for Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

Dominic E. Sanford, Brian A. Belt, Roheena Z. Panni, Allese Mayer, Anjali D. Deshpande, Danielle Carpenter, Jonathan B. Mitchem, Stacey M. Plambeck-Suess, Lori A. Worley, Brian D. Goetz, Andrea Wang-Gillam, Timothy J. Eberlein, David G. Denardo, Simon Peter Goedegebuure, David C. Linehan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (13): 3404–3415.
https://doi.org/10.1158/1078-0432.CCR-13-0525
Published: 30 June 2013
View article titled, Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
Open the PDF for Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis in another window
Includes: Supplementary data
Journal Articles

Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer

Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, Andrew M. Lowy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 538–540.
https://doi.org/10.1158/1078-0432.CCR-12-2745
Published: 31 January 2013
View article titled, Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
Open the PDF for Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer in another window